

The polyphenol EGCG inhibits amyloid formation less efficiently at phospholipid interfaces than in bulk solution

Maarten F.M. Engel[†], Corianne C. vandenAkker[†], Michael Schleege[‡], Krassimir P. Velikov^{§,¶}, Gijsje H. Koenderink[†], Mischa Bonn^{†,‡,*}

[†] FOM Institute AMOLF, Science Park 104, 1098 XG, Amsterdam, The Netherlands

[‡] Max Planck Institute for Polymer Research, Department of Molecular Spectroscopy, Ackermannweg 10, 55128 Mainz, Germany

[§] Unilever R&D Vlaardingen, Olivier van Noortlaan 120, 3133 AT Vlaardingen, The Netherlands

[¶] Soft Condensed Matter, Debye Institute for Nanomaterials Science, Department of Physics and Astronomy, Utrecht University, Princetonplein 5, 3584 CC, Utrecht, The Netherlands

KEYWORDS amyloids, protein nanofibril, misfolding, hIAPP, inhibition, (-)epigallocatechin gallate, vibrational sum-frequency generation, AFM, FT-IR

Supporting Information Placeholder

ABSTRACT: Age-related diseases like Alzheimer's disease and type 2 diabetes mellitus are characterized by protein misfolding and the subsequent pathological deposition of fibrillized protein, also called amyloid. Several classes of amyloid-inhibitors have recently been tested, traditionally under bulk conditions. However, it has become apparent that amyloid fibrils and oligomers assemble and exert their cytotoxic effect at cellular membranes, rather than in bulk solution. Knowledge is therefore required of inhibitor activity specifically at the phospholipid membrane interface. Here we show, using surface-specific sum-frequency generation (SFG) spectroscopy and atomic force microscopy (AFM), that the commonly used (-)epigallocatechin gallate (EGCG) is a much less efficient amyloid inhibitor at a phospholipid interface than in bulk solution. Moreover, EGCG is not able to disaggregate existing amyloid fibrils at a phospholipid interface, in contrast to its behavior in bulk. Our results show that interfaces significantly affect the efficiency of inhibition by EGCG inhibitors and should therefore be considered during the design and testing of amyloid inhibitors.

INTRODUCTION

Many protein misfolding diseases such as Alzheimer's disease and type 2 diabetes mellitus are characterized by the pathological deposition of amyloid fibrils.¹⁻³ Current hypotheses suggest that these fibrils, and/or their oligomeric precursors, cause cell death by disrupting cellular membranes.⁴⁻⁶ Consequently, the inhibition of the formation of fibrils or oligomers has been a focus in the development of drugs for misfolding diseases.^{7,8} In recent years several types of inhibitors have been tested for their ability to reduce amyloid cytotoxicity, using either cells⁹⁻¹² or in vitro model systems.¹³⁻¹⁷ An important class of inhibitors is made up of polyphenols, which are thought to interact with amyloidogenic proteins via aromatic pi-pi interactions,^{13,14,18-20} though the precise mechanism is an issue still under debate.^{21,22} A particularly promising inhibitor is (-)epigallocatechin gallate (EGCG), a natural component of green tea. This polyphenol inhibits fibrillation of several amyloidogenic peptides^{9,20,23-25} and has even been shown to disaggregate existing fibrils.^{22,23,26,27} Further, EGCG protects cells against amyloid-induced toxicity.^{9,22,23} During *in vitro* studies, inhibitors are typically tested under bulk conditions, for which aggregating peptide and inhibitor are diffusing freely in solution, as has also been the case for studies on EGCG.^{9,22-27} However, it is the cellular membrane, and not bulk solution, where amyloid fibrils and oligomers are thought to assemble and exert their cytotoxic effect.⁴⁻⁶ In recent experiments on lipid- or glycosaminoglycan-mediated amyloid formation, modifications of inhibitor effectivity could be demonstrated.²⁸⁻³¹ It is therefore vital to know whether inhibitors are also effective at the phospholipid membrane interface.

Many techniques have become available for measuring fibril formation and its inhibition in bulk solution, such as the thioflavin T (ThT) assay and electron microscopy.³² However, here we want to study these processes specifically and exclusively at the phospholipid interface. We exploit the unique sensitivity and spatial selectivity of vibrational sum-frequency generation (VSFG) to study amyloid fibrillation at the phospholipid interface. This approach was recently pioneered by the Yan group.^{33,34} Here we use this technique to elucidate the effect of EGCG on fibril formation. In addition, atomic force microscopy (AFM) in combination with the Langmuir Blodgett technique, to selectively probe only interfacial molecules, is used to investigate the morphology of species produced during aggregation at the phospholipid interface.

VSFG provides information about the conformation and orientation of molecules at interfaces.³⁴⁻³⁶ In VSFG, two pulsed laser beams, one at visible and one at infrared (IR) frequency, are focused to overlap at the interface. As a result of the interaction of the laser fields with molecules at the surface – and only those at the surface – light at the sum-frequency of the visible and IR beams may be generated. When the IR frequency matches that of a surface vibrational mode, this process may be resonantly enhanced. Protein conformations can be investigated through the C=O vibrations of the protein backbone (amide I region, 1600-1700 cm⁻¹), where the characteristic β -sheet structure of amyloid fibrils can be distinguished from structures such as random coil and α -helix.³⁷ VSFG spectroscopy is a sensitive, label-free method that so far has seen limited application in the study of interfacial amyloid secondary structure.^{33,34,38}

Human islet amyloid polypeptide (hIAPP) forms fibrillar amyloid deposits in the pancreatic islets of Langerhans of patients with type 2 diabetes mellitus.² hIAPP fibrils and/or oligomers are thought to be involved in the death of the insulin-producing cells in these islets.^{2-4,6} Like many amyloidogenic peptides, non-aggregated hIAPP is mainly unstructured while fibrillar hIAPP is rich in β -sheet structure.³⁹ Current models of membrane-mediated IAPP fibrillation are based on transiently populated α -helical intermediates.^{40,41} It is thought that binding of these species to the membrane surface, especially the attachment of cationic amino acid residues to anionic membranes, facilitates an increase in the local protein concentration. Thereby conformational switching from helical to β -sheet structures and subsequent fibril growth is mediated. Different mechanisms of how amyloids induce cytotoxicity have been proposed,^{42,43} such as the disruption of membranes by pore formation or nonspecific interaction.⁴⁴ We have chosen hIAPP for two reasons. First, the details of the aggregation of hIAPP, both in bulk and at the interface, have been described extensively.^{3,39,45-48} Second, a recent study has shown that EGCG efficiently inhibits hIAPP aggregation in bulk.²³ As a model membrane, we use monolayers of the negatively charged lipid 1,2-dihexadecanoyl-*sn*-glycero-3-phospho-(1'-*rac*-glycerol) (DPPG), since IAPP-lipid interactions have been investigated extensively with this system.^{33,47,49} Also, DPPG accelerates IAPP aggregation, which allows for reasonable VSFG measuring times.³³

Here we combine VSFG with AFM to investigate IAPP aggregation and its inhibition by EGCG exclusively at a phospholipid interface. We demonstrate that EGCG has a strongly reduced efficiency to inhibit the formation of hIAPP amyloid fibrils at the phospholipid interface, in contrast to its behavior in bulk. Moreover, we show that while EGCG disaggregates hIAPP fibrils in bulk, EGCG has no effect on fibrils at the phospholipid interface, even when present in large molar excess.

EXPERIMENTAL SECTION

Preparation of solutions and monolayers. Synthetic hIAPP (Bachem H-7905) stock solutions were prepared by dissolving freeze-dried peptide powder in Milli-Q water to a final concentration of approximately 1 mg/ml. This solution was filtered using a 0.2 μ m filter. Immediately afterwards, the concentration of hIAPP was measured using the absorbance at 280 nm and the known extinction coefficient of 1,280 $\text{cm}^{-1}\text{M}^{-1}$.⁵⁰ The final concentration of the stock solution was typically between 120 and 160 μ M. The solution was aliquoted and immediately stored at -80 °C until use. Once thawed, the contents of the tube were used within minutes, and left-over solution was discarded. (–)-Epigallocatechin gallate (>95%) (EGCG, Sigma-Aldrich E4143) stock solutions were freshly prepared before each experiment as a 1 mM solution in Milli-Q water. All experiments were performed using a 10 mM sodium phosphate buffer at pH 7.4 which was filtered using a 0.2 μ m filter before each experiment. The monolayer was prepared in a circular Teflon trough with a diameter of 80 mm. First, the trough was filled with 25 ml buffer either with or without 1 μ M EGCG. Next, hIAPP stock solution was added to obtain a final hIAPP concentration of 1 μ M. The solution was carefully mixed by pipetting up and down using a 1 ml pipette. After incubation for 10 to 15 minutes, sixteen 0.5 μ l drops of a 1 mM solution of DPPG (Avanti Polar Lipids) in chloroform were evenly spread on the surface to ob-

tain 107 \AA^2 per phospholipid molecule (defined in absence of peptide).

These conditions were chosen in accordance with recent experiments of Fu et al.³³ The resulting surface pressure is around 30 mN/m, corresponding to the packing density of lipids in biological membranes.⁵¹ The phospholipid-hIAPP interface was heterogeneous, i.e. SFG spectra were different at different locations at the interface likely due to clustering of fibrils (see Supplementary Fig. S5 online). To average the signal over a large surface area, the trough was rotated at approximately 10 rpm.

Vibrational sum-frequency generation (VSFG) spectroscopy. The vibrational sum-frequency generation (VSFG) spectroscopy setup has been described in detail elsewhere.⁵² Briefly, a visible beam (VIS) (800 nm, 20-30 μ J/pulse, spectral bandwidth of 25 cm^{-1}) is overlapped at the sample position with an infrared (IR) beam (2-3 μ J/pulse, 150 fs broadband) which is centered at 1,675 cm^{-1} and has a spectral bandwidth of 150 cm^{-1} . Both beams are focused down to an approximately 100 μ m beam waist. The incident angles of the VIS and IR beams are 35° and 40°, respectively, both defined relative to the surface normal. The SFG light generated by the sample is detected with a monochromator connected to a charge-coupled device camera. All spectra were collected at 23.0 ± 0.2 °C under unpolarized SFG, s-polarized VIS, and p-polarized IR conditions and integrated over 6 min. In contrast to recently published VSFG data on hIAPP aggregation,³³ we observe no amide I signal for hIAPP fibrillation using psp polarization conditions (corresponding to p-polarized SFG, s-polarized VIS, and p-polarized IR settings).³⁸ To not unnecessarily lose signal photons, we decided to omit the output polarizer. Spectral analysis included background subtraction and division by the reference signal from a z-cut quartz plate that was taken immediately before or after the spectrum of the monolayer. Spectral fitting was performed using a three-component (2 for the amide I signal and 1 for the phospholipid signal) Lorentzian model and included maximum entropy method (MEM) analysis to verify the fit.³⁵ The equation used for the fit has been described previously and is commonly used to fit VSFG spectra.^{33,35,37} The fitting procedure yields values for the amplitude and phase of the non-resonant susceptibility, and for the amplitude, wavenumber and line width (full width at half maximum, FWHM) of each component, as shown in Supplementary Tables S1 and S2 online. Fitting was performed in Igor Pro 6.2 (WaveMetrics, Inc.) using a global fit procedure for all spectra from a single aggregation experiment, with the non-resonant contribution, the wavenumber, the full width at half height, and the peak maximum position linked for all spectra during the fit. The relative contribution of each component in the amide region was calculated by dividing the amplitude by the FWHM, followed by normalization to the maximum of the amide signal intensity. For the 1,672 cm^{-1} component, this value is named "SFG β -sheet/turn", as plotted in Figs. 2a and 3b. The value obtained is proportional to the amount of secondary structure when assuming (i) that the IR and Raman dipole do not depend on the secondary structure and (ii) that orientation effects are cancelled out by the random orientation of the fibrils in the plane of the surface. The error is estimated to be ± 0.07 (a.u.) for all SFG data points in Figs. 2a and 3b, based on the variation in fit results when different fit assumptions are made (for example, with or without requiring the widths of the resonances to be identical for all fits).

Atomic Force Microscopy (AFM). Samples for AFM were prepared using the Langmuir Blodgett technique and a MicroTrough X (Kibron). The trough area was filled with 55 ml buffer, with or without 1 μ M EGCG, and the surface area was set to 110 cm^2 using movable barriers to obtain the same area to volume ratio as in the trough used for SFG measurements. A freshly cleaved piece of mica (15x15 mm) was submerged and hIAPP was added to obtain a final concentration of 1 μ M. The solution was carefully mixed by pipetting up and down using a 1 ml pipette. After a stable surface pressure of approximately 20 mN/m was reached, 32 0.5 μ l drops of a 1 mM solution of DPPG in chloroform were evenly spread over the surface to obtain 107 \AA^2 per lipid (defined in absence of peptide) after which the surface pressure increased to 30 mN/m. Next, the mica was pulled up through the surface at 5 mm/min while maintaining a constant surface pressure of 30 mN/m. The mica was air dried and used for AFM analysis using tapping mode AFM in air (Dimension 3100 Scanning Probe Microscope, Veeco). Silicon cantilevers with a force constant of 5 N/m were used. Images were flattened using Nanoscope 6.14 software. For analysis of samples from the ThT test (see below), 40 μ l samples were taken from the wells of the microtiter plates (see below), and incubated for 5 min on freshly cleaved mica, washed 2 to 3 times with 1 ml of Milli-Q water, and air dried. For the AFM analysis of the ThT experiment, a concentration of 10 μ M hIAPP was used since 1 μ M was too low for AFM analysis of bulk aggregation. The ThT curves for 10 μ M also show complete inhibition of fibril formation in the presence of EGCG.

Thioflavin T kinetics. The kinetics of hIAPP fibril formation was measured using the fluorescence intensity increase upon binding of the fluorescent dye Thioflavin T (ThT) to hIAPP fibrils, a commonly used method to detect amyloid fibrils.⁵³ A plate reader (PerkinElmer Victor X3) was used to perform ThT experiments in standard 96-well flat-bottom black microtiter plates (Nunc 237105) in combination with a 430 nm excitation filter and a 480 nm emission filter. The assay was started by adding a few μ l of a 140 μ M hIAPP stock solution in Milli-Q to a solution of 10 μ M ThT in 10 mM sodium phosphate at pH 7.4. The final hIAPP concentration was either 1 or 10 μ M, and the total volume in each well was 150 μ l. When required, EGCG (at a final concentration of 1 or 10 μ M, always at a 1:1 molar ratio of hIAPP:EGCG) was added before the addition of hIAPP. The microtiter plate was covered using a transparent self-adhesive film to prevent evaporation from the wells. The microtiter plate was shaken before the measurement for 10 s by using the shaking function of the plate reader. Fluorescence was measured from the top every 5 min at 23 ± 1 $^\circ\text{C}$.

Fourier transform infrared spectroscopy (FT-IR). Infrared transmission measurements were carried out on a Vertex 70 FT-IR spectrometer (Bruker Optics, Ettlingen, Germany) using a deuterated triglycine sulfate detector (DTGS). The spectral resolution was 4 cm^{-1} and for each measurement 256 spectra were averaged. The Blackmann-Harris-3-Term apodization function was used for the Fourier transformation. Bulk fibrils of hIAPP were grown in a 10 μ M solution for 18 h while agitated. The sample was concentrated by ultrafiltration using centrifugal filters with molecular weight cutoff of 10 kDa (Amicon Ultra-4, Millipore, Cork, Ireland). The aqueous

buffer was exchanged by a deuterium oxide based sodium phosphate buffer at pD 7.4 by 10-fold dilution and concentration for 3 times. The sample of the approximate concentration of 200 μ M was incubated for 5 h to allow for a full H/D exchange. The fibril suspension was mixed with an EGCG solution in deuterium oxide to yield a 1:1 molar ratio. The FT-IR transmission cuvette based on two CaF_2 windows was immediately assembled under a stream of nitrogen, and sealed with vacuum grease (Baysilone-Paste, Bayer, Leverkusen, Germany). Spectral recording was started 20 min after mixing of the fibrils with EGCG, due to the assembling of the cuvette and the depletion time of atmospheric water vapor in the spectrometer. Spectra were recorded every 5 min for 12 hrs. No baseline correction was performed; the 2nd derivative spectra were calculated using the OPUS software. Attenuated total reflection (ATR) spectra were measured on a single reflection ATR cell equipped with a diamond crystal (Spectra-Tech Foundation Performer, Thermo Scientific, Waltham, MA) on a Nicolet 730 FT-IR spectrometer (Thermo Scientific). 5 μ l of the aqueous hIAPP sample were deposited on the ATR crystal by drying at room temperature.

RESULTS

We used VSFG and AFM to gain insight into the inhibition of amyloid fibril formation by EGCG specifically at the physiologically relevant phospholipid interface. The phospholipid interface was obtained by depositing phospholipid molecules at the air/water interface of a buffered solution of hIAPP molecules in a trough. First, we examined assembly of hIAPP into amyloid fibrils at the phospholipid interface in the absence of EGCG. Addition of non-aggregated hIAPP to buffer, to a final peptide concentration of 1 μ M, resulted in an increase of the surface pressure to approximately 20 mN/m, showing that non-aggregated hIAPP is surface active, like many amphiphilic peptides. This observation is in agreement with earlier studies of hIAPP⁴⁶ and other amyloidogenic proteins and peptides.^{54,55} Subsequently, the negatively charged phospholipid DPPG was deposited at the interface up to a surface pressure of approximately 30 mN/m, which corresponds to the packing density of lipids in biological membranes.⁵¹ At this surface pressure, a DPPG monolayer adopts at room temperature the liquid condensed phase.⁵⁶ In the absence of lipids, hIAPP does not convert to β -sheet-rich structures on the time scale of our SFG experiments (see Supplementary Fig. S1 and Table S3 online). We exclude the presence of pre-existing aggregates by the fact that we observe a characteristic lag phase in Thioflavin T fluorescence assays. Presence of pre-existing aggregates would have resulted in an immediate increase in fluorescence intensity.¹ Additionally, no amyloid fibrils are observed by AFM 10 min after adding lipids to the freshly prepared hIAPP solution (Fig. 1a). However, after 17 hrs of incubation, the interface showed the abundant presence of fibrils with diameters in the range of 3 to 7 nm, typical of amyloid fibrils (Fig. 1b).

VSFG enabled us to follow the kinetics of fibrillation specifically at the phospholipid interface, as shown in Fig. 1d. The peptide and the phospholipid both contribute to the spectra, but in different wavenumber regions.




Figure 1. AFM images and SFG spectra measured during hIAPP aggregation at the phospholipid interface in the presence or absence of EGCG. (a) AFM images after hIAPP aggregation for 10 min and (b) 1020 min in the absence of EGCG, and (d) VSFG spectra taken at various time points. (c) AFM image after hIAPP aggregation in the presence of EGCG at a 1:1 hIAPP:EGCG molar ratio for 1020 min, and (e) corresponding VSFG spectra. The vertical dashed lines in panels d and e indicate IR frequencies of 1,652 and 1,672 cm^{-1} , respectively. Red lines through the bottom spectra are exemplary results of the global fit; the dashed red lines show the three individual components of each fit.

The phospholipid displays a carbonyl stretch vibration around 1,730 cm^{-1} , while the peptide shows peaks in the amide I region (1,600-1,700 cm^{-1}). Note that EGCG has no vibrational modes in this frequency region. We have fit a three-component Lorentzian function to the SFG spectra using one component for the carbonyl stretch vibration of DPPG (1,730 cm^{-1}) and two components to describe the amide I region (see Methods and a list of fit parameters in Supplementary Tables S1 and S2 online; an example fit to the spectrum after 14 min is shown as a red line in Fig. 1d). The two amide I components are centered at 1,652 and 1,672 cm^{-1} , suggesting a contribution of α -helix or random structure and β -sheet or turns, respectively.^{33,34,36,57,58} At early times, the amide I region is dominated by α -helix or random structure (1652 cm^{-1}), between which we cannot distinguish. These spectra are consistent with the AFM images showing that the peptide is initially non-aggregated. However, as time progresses, the contribution of β -sheet/turns (1,672 cm^{-1}) increases. After 8-10 hrs, the peptide is fully converted from α -helix or random structure to β -sheet or turns, consistent with prior SFG measurements.^{33,34} As amyloid fibrils are characterized by the dominant presence of β -sheet content, we assign the increase in the 1,672 cm^{-1} component mainly to increased β -sheet structure, rather than β -turns.^{33,34,36,57,58} We assume, that the β -sheet content is directly related to formation of mature fibrils. In the absence of lipids, hIAPP does not convert to β -sheet rich structures at the surface on the time scale of our SFG experiment (see Supplementary Fig. S1 and Table S3 online). This confirms the catalyzing role

of lipids in hIAPP aggregation, observed previously for liposomes.⁴⁹

To assess the influence of EGCG on fibrillation both in bulk solution and at the phospholipid interface, we followed hIAPP fibrillation in both situations in the presence of an equimolar amount (1 μM) of EGCG. For the quantification of bulk fibril formation, we use a Thioflavin T assay, in which the Thioflavin fluorescence serves as a reporter for the presence of fibrils (Fig. 2a).⁵³ Note that the Thioflavin T assay cannot separate interfacial and bulk-contributions to the fluorescence; its application is therefore restricted to bulk experiments. In agreement with previous reports in bulk,²³ 1 μM of EGCG suffices to completely inhibit hIAPP aggregation in bulk experiments: the Thioflavin fluorescence is completely suppressed in the presence of EGCG. AFM images confirm that no fibrils are formed under bulk conditions when EGCG is present at an equimolar concentration (Fig. 2c), whereas abundant fibrils are present in absence of EGCG (Fig. 2b). In contrast, the EGCG inhibitory activity is much reduced at the phospholipid interface: AFM images of the interface transferred onto mica showed the abundant presence of fibrils (Fig. 1c), despite the presence of EGCG. Consecutive VSFG spectra taken during 24-hr incubation of hIAPP in the presence of EGCG confirmed that there was significant conversion of hIAPP secondary structure from α -helix or random structure (1,652 cm^{-1}) to β -sheet (1,672 cm^{-1}) (see Fig. 1e). However, the shift in peak position of the entire amide I band, which is a convenient indicator of peptide aggregation,³³ is significantly less in the presence of EGCG (7 cm^{-1}) than in its absence (20 cm^{-1}). Note




Figure 2. Comparison of the inhibitory effect of EGCG on hIAPP fibrillation in bulk and at the phospholipid interface. (a) The formation of hIAPP amyloid fibrils in bulk was measured using a Thioflavin T fluorescence assay, showing the characteristic sigmoidal increase in fibril yield in the absence of EGCG (\times) and virtually complete inhibition of fibril growth in the presence of EGCG at a 1:1 molar ratio (+). The formation of amyloid fibrils at the phospholipid interface was measured by determining the relative β -sheet intensity from the VSFG spectra, in absence (\diamond) and presence of EGCG (\square). AFM confirms that (b) hIAPP fibrils have grown in bulk solution in the absence of EGCG, and that (c) an equimolar amount of EGCG completely inhibits fibril formation. From the SFG results, it is apparent that the inhibition efficiency of EGCG is much reduced at the lipid interface.

that the relative SFG intensities of the phospholipid and hIAPP contributions in spectra taken in the presence of EGCG (approximately 0.8 and 5 a.u., respectively) are different than in the spectra taken in its absence (approximately 1 and 3 a.u., respectively), due to slightly smaller amounts of lipids that were deposited on the subphases for the experiment with EGCG. Fewer lipids result in a lower signal at $1,730\text{ cm}^{-1}$ and leave more room at the surface for fibrils, causing a larger intensity in the $1,652\text{ cm}^{-1}$ region. These small differences in surface lipids do not affect the interfacial fibrillation kinetics. To obtain quantitative information about the inhibition of hIAPP fibrillation at the phospholipid interface by EGCG, we fitted the contributions of the α -helix/random structure ($1,652\text{ cm}^{-1}$) component and the β -sheet ($1,672\text{ cm}^{-1}$) component during hIAPP aggregation. Both contributions are expressed as the amplitude of the contribution to interfacial vibrational response divided by the full width at half-height (see Methods and Supplementary Tables S1 and S2 online). The resulting values are normalized so that at every time the total amide I contribution equals one. As shown in Fig. 2a, the relative amount of β -sheet intensity increases with time, both in the presence and absence of EGCG. However, in the presence of EGCG, the spectral amplitude reflecting the formation of β -




Figure 3. Effect of EGCG on preformed hIAPP fibrils in bulk and at the surface. (a) Kinetics of disaggregation of preformed hIAPP fibrils with EGCG at a 1:1 molar ratio in bulk, followed by a ThT assay (\times), compared to disaggregation at a lipid interface, followed by SFG (\square). The dotted line at $t=0$ indicates the time of addition of EGCG to the fibrils. (b) The relative β -sheet/turn intensity from the VSFG spectra for incubation of preformed hIAPP fibrils for 1 hr at the phospholipid interface (\times) as function of EGCG concentration. Incubations for 24 hrs at 1 mM EGCG are also shown (\circ). The inset shows an AFM image of abundant hIAPP fibrils that remain at the DPPG interface after incubation with 100 μ M EGCG for 24 hrs. The SFG spectra and fit parameters of the data in this figure are shown in Supplementary Fig. S2 and Tables S4 and S5 online.

sheet structure is reduced by a factor two. This suggests that, while it shows some activity also at the phospholipid interface, EGCG is markedly less effective at the interface than in bulk, where the inhibition is close to 100% in the same time (Fig. 2a).

Another characteristic of EGCG that has been demonstrated under bulk conditions is its ability to disaggregate existing fibrils into unstructured smaller species.^{9,23,26,27} We indeed observe this effect in our ThT assays when adding EGCG to preformed hIAPP fibrils in bulk conditions (Fig. 3a), and we confirmed the breakdown of fibrils by AFM. Next, we asked whether EGCG is also able to reduce the β -sheet content of existing hIAPP fibrils at the phospholipid interface. We formed hIAPP fibrils at the phospholipid interface by incubation for 17 hrs in absence of EGCG, and then recorded VSFG spectra during the incubation of EGCG with the pre-existing fibrils. These measurements showed that the β -sheet content of hIAPP fibrils at the interface, at a bulk hIAPP concentration of




Figure 4. Second derivatives of the FT-IR absorption spectra in the spectral region of the amide I vibrational band of (a) the ATR-spectrum of the dry hIAPP fibril film and (b) the transmission spectra of the hIAPP disaggregation kinetics upon EGCG addition. The minima identify the center of the absorption bands, contributing to the respective FT-IR absorption spectrum. Bands at 1,625 and 1,673 cm^{-1} reveal the low and high frequency contribution of β -sheet secondary structure, present in the ATR spectrum and in the early kinetic spectra.

1 μM , is not reduced by 1 μM EGCG, even after incubation for two days, in strong contrast with the situation in bulk (Fig. 3a). Moreover, even at EGCG to hIAPP molar ratios of up to 1000, no disaggregation of interfacial hIAPP fibrils was observed, even after 24 hrs of incubation (Fig. 3b). AFM measurements confirm that hIAPP fibrils indeed remain at the lipid interface (inset Fig. 3b).

To test whether a structurally different type of fibrils is formed at the interface which is more resistant to EGCG than fibrils formed in bulk solution, we investigated the effect of EGCG on interfacial fibrils in the absence of lipids. Fibrils were collected after overnight incubation at the lipid interface. AFM imaging showed that preformed interfacial fibrils are disaggregated upon incubation with EGCG in bulk (Supplementary Fig. S6), which strongly suggests that the apparent resistance of hIAPP amyloids against EGCG at the lipid monolayer interface is not an intrinsic (e.g. structural) property of the interfacial amyloid fibril itself.

In the analysis of the VSFG data we assume a direct correlation between β -sheet content of hIAPP and the formation of mature fibrils. From VSFG data, we cannot exclude, however, the presence of oligomeric forms of hIAPP containing β -sheet structure elements. Such oligomers might form as intermedi-

ates during fibrillogenesis or upon disaggregation by EGCG. To confirm that the β -sheet content is indeed an unambiguous marker of the fibril state of hIAPP, FT-IR experiments were performed. Changes in the secondary structure of hIAPP fibrils grown in bulk solution upon addition of EGCG were investigated by changes in the amide I absorption band. EGCG does not exhibit any FT-IR absorption band centered between 1,680 and 1,615 cm^{-1} (data not shown). Figure 4 shows the second derivative of the FT-IR absorption spectra (c.f. Supplementary Fig. S7 online for the raw absorption spectra). The air-dried hIAPP film yields a pronounced amide I band. The minima in the respective 2nd derivative spectrum identify the various distinct contributions to the amide I band related to different secondary structure types (Fig. 4 a). The predominant β -sheet character of the dry amyloid sample is evident by a pronounced minimum at 1,625 and a weaker one at 1,673 cm^{-1} . Their spectral positions appear at remarkable low wavenumbers, indicating the strong hydrogen bond interactions typical for amyloids. The latter minimum coincides with the β -sheet marker band present in the VSFG spectra (Fig 1d,e). The position of two additional minima at 1,646 and 1,662 cm^{-1} may originate from smaller contributions of helical and/or unordered structures in hIAPP fibrils.⁵⁹ Structural transitions during the dissolution process of a 1:1 molar mixture of hIAPP fibrils and EGCG are followed by transmission FT-IR. The sample was suspended in deuterium oxide buffer to separate the amide I vibration from the water bending vibrational mode. Whereas the FT-IR absorption bands in the unaltered absorption spectra were low in intensity and the amide I band was affected by the broad background contribution of deuterium oxide centered at 1,555 cm^{-1} (c.f. Supplementary Fig. S7b online), the 2nd derivative spectra clearly identify the different contributions to the amide I spectra (Fig. 4b). The first spectrum, taken 20 min after mixing EGCG and hIAPP fibrils, strongly resembles the 2nd derivative spectrum of the dry hIAPP fibrils (Fig. 4a), indicating the predominant amyloid state of the sample. Slight shifts of the position of the minima can be attributed to the H/D exchange and the ongoing disaggregation process. The time dependence of disaggregation is demonstrated by the 2nd derivative spectra measured at selected time points after mixing the hIAPP fibrils with EGCG as indicated in the legend of figure 4b. All minima corresponding to the fibril state of hIAPP disappear successively within 130 min, most notably, including the minima corresponding to the β -sheet content of the sample. Simultaneously a new minimum is formed at 1,652 cm^{-1} , which can be attributed to the formation of an α -helix.⁵⁹ The high α -helical content of the disaggregation products suggests that monomeric hIAPP is formed.⁶⁰ These results clearly demonstrate that a break-up of fibrillar structures would be apparent from the SFG spectra. The fact that the SFG intensity associated with β -sheet content remains after addition of EGCG thus demonstrates the inability of EGCG to disrupt fibrils at the lipid interface.

DISCUSSION

By using VSFG supported by FT-IR in combination with AFM, we were able to show that EGCG has a considerably lower capacity towards the inhibition of hIAPP fibril formation at a phospholipid interface and is unable to disrupt the β -sheet structure of existing fibrils, in strong contrast with the efficient inhibition of fibril formation and disruption of pre-existing fibrils in bulk. The phospholipid monolayer apparently stabilizes the fibrils towards EGCG. This stabilization is the

result of non-covalent interactions at the interface, enabled by the amphiphilicity of both fibrils and lipids. The interaction between lipids and fibrils at the surface is also apparent from the contribution to the surface tension of both entities.

The molecular origin of the low fibril-inhibition efficiency of EGCG at the interface likely originates from the simple inability of EGCG to access the binding site on the peptide due to the peptide's presence at the interface. EGCG has been suggested to interact with amyloidogenic peptides and proteins via aromatic residues.^{14,15,20} These hydrophobic aromatic residues will be contained within the hydrophobic part of the phospholipid/air interface, rather than pointing towards bulk water. EGCG is simply not present in the interfacial hydrophobic region as is evident from: (i) the absence of an increase of the surface pressure when EGCG is added under an air/water or an air/DPPG interface (see Supplementary Fig. S3 online), and (ii) the absence of SFG signal in the CH stretch spectral region (2,800-3,200 cm⁻¹) from an EGCG solution interface (see Supplementary Fig. S4 online). A role may also be played by the competitive interaction of EGCG with lipids, which would serve to further reduce its effective interfacial concentration. Indeed, EGCG has been reported to interact with the neutral phospholipid dipalmitoylphosphatidylcholine (DPPC), and to a lesser extent with negatively charged lipids.^{61,62} Hence the low interfacial fibril disaggregation efficiency of EGCG is concluded to result from a negligibly low interfacial concentration of EGCG. This effect cannot even be negated by increasing the bulk concentration by several orders of magnitude (Fig. 3b).

Disaggregation experiments of interfacial fibrils in the absence of lipids demonstrate that their resistance against EGCG is not a property of the fibrils itself, as it would be the case, if fibrils formed at the lipid interface are different from fibrils in bulk solution (Supplementary Fig. S6 online). This observation is consistent with the hypothesis that the EGCG is simply not interacting with the fibrils at the lipid interface.

The combined results presented here demonstrate that EGCG only partially inhibits the formation of β -sheet structure at the phospholipid interface, being approximately 50% less efficient at the interface compared to bulk. Moreover, EGCG is not able to disaggregate existing fibrils at an interface during the course of our experiments: the phospholipid interface negatively affects the efficiency of the inhibitor. Given that current hypotheses suggest that it is the cellular membrane where amyloid fibrils and oligomers assemble and exert their cytotoxic effect, phospholipid interfaces should be considered during the design and in vitro testing of amyloid inhibitors. We show here that SFG spectroscopy in conjunction with AFM provides a useful assay for testing the activity of amyloid inhibitors specifically at interfaces.

ASSOCIATED CONTENT

Supporting Information. VSFG spectra together with the respective fit parameters of the spectra can be obtained from the Supporting Information. Also included are AFM images of interfacial fibrils in the absence of lipids and the FT-IR absorption spectra corresponding to the presented 2nd derivative spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

bonn@mpip-mainz.mpg.de

ACKNOWLEDGMENT

This work is part of the Industrial Partnership Programme (IPP) Bio-(Related) Materials (BRM) of the Stichting voor Fundamenteel Onderzoek der Materie (FOM), which is financially supported by the Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO). The IPP BRM is co-financed by the Top Institute Food and Nutrition and the Dutch Polymer Institute. This work is further supported by NanoNextNL, a micro and nanotechnology consortium of the Government of the Netherlands and 130 partners.

REFERENCES

- (1) Chiti, F.; Dobson, C. M. *Annu. Rev. Biochem.* **2006**, *75*, 333.
- (2) Höppener, J. W. M.; Ahrén, B.; Lips, C. J. M. *N. Engl. J. Med.* **2000**, *343*, 411.
- (3) Engel, M. F. M. *Chem. Phys. Lipids* **2009**, *160*, 1.
- (4) Kaye, R.; Head, E.; Thompson, J. L.; McIntire, T. M.; Milton, S. C.; Cotman, C. W.; Glabe, C. G. *Science* **2003**, *300*, 486.
- (5) Lashuel, H. A.; Lansbury, P. T. *Q. Rev. Biophys.* **2006**, *39*, 167.
- (6) Engel, M. F. M.; Khemtémourian, L.; Kleijer, C. C.; Meeldijk, H. J. D.; Jacobs, J.; Verkleij, A. J.; de Kruijff, B.; Killian, J. A.; Höppener, J. W. M. *Proc. Natl. Acad. Sci. U.S.A.* **2008**, *105*, 6033.
- (7) Cohen, F. E.; Kelly, J. W. *Nature* **2003**, *426*, 905.
- (8) Herczenik, E.; Gebbink, M. F. B. G. *FASEB J.* **2008**, *22*, 2115.
- (9) Bieschke, J.; Russ, J.; Friedrich, R. P.; Ehrnhoefer, D. E.; Wobst, H.; Neugebauer, K.; Wanker, E. E. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 7710.
- (10) Daval, M.; Bedrood, S.; Gurlo, T.; Huang, C. J.; Costes, S.; Butler, P. C.; Langen, R. *Amyloid J. Prot. Fold. Disord.* **2010**, *17*, 118.
- (11) Alhamadsheh, M. M.; Connelly, S.; Cho, A.; Reixach, N.; Powers, E. T.; Pan, D. W.; Wilson, I. A.; Kelly, J. W.; Graef, I. A. *Sci. Transl. Med.* **2011**, *3*.
- (12) Bulic, B.; Pickhardt, M.; Mandelkow, E. M.; Mandelkow, E. *Neuropharmacology* **2010**, *59*, 276.
- (13) Gazit, E. *FASEB J.* **2002**, *16*, 77.
- (14) Shoval, H.; Lichtenberg, D.; Gazit, E. *Amyloid* **2007**, *14*, 73.
- (15) Necula, M.; Kaye, R.; Milton, S.; Glabe, C. G. *J. Biol. Chem.* **2007**, *282*, 10311.
- (16) Sellin, D.; Yan, L.-M.; Kapurniotu, A.; Winter, R. *Biophys. Chem.* **2010**, *150*, 73.
- (17) Buell, A. K.; Esbjorner, E. K.; Riss, P. J.; White, D. A.; Aigbirhio, F. I.; Toth, G.; Welland, M. E.; Dobson, C. M.; Knowles, T. P. J. *Phys. Chem. Chem. Phys.* **2011**, *13*, 20044.
- (18) Porat, Y.; Abramowitz, A.; Gazit, E. *Chem. Biol. Drug. Des.* **2006**, *67*, 27.
- (19) Hudson, S. A.; Ecroyd, H.; Dehle, F. C.; Musgrave, I. F.; Carver, J. A. *J. Mol. Biol.* **2009**, *392*, 689.
- (20) Lopez Del Amo, J. M.; Fink, U.; Dasari, M.; Grelle, G.; Wanker, E. E.; Bieschke, J.; Reif, B. Structural Properties of EGCG-Induced, Nontoxic Alzheimer's Disease A β Oligomers. *J. Mol. Biol.* [Online early access]. DOI: 10.1016/j.jmb.2012.01.013. Published Online: Jan 28, 2012. <http://www.sciencedirect.com/science/article/pii/S0022283612000678> (accessed July 11, 2012).
- (21) Armstrong, A. H.; Chen, J.; McKoy, A. F.; Hecht, M. H. *Biochemistry-Us* **2011**, *50*, 4058.
- (22) Ehrnhoefer, D. E.; Bieschke, J.; Boeddrich, A.; Herbst, M.; Masino, L.; Lurz, R.; Engemann, S.; Pastore, A.; Wanker, E. E. *Nat. Struct. Mol. Biol.* **2008**, *15*, 558.
- (23) Meng, F.; Abedini, A.; Plesner, A.; Verchere, C. B.; Raleigh, D. P. *Biochemistry-Us* **2010**, *49*, 8127.
- (24) Norton, R. S.; Chandrashekar, I. R.; Adda, C. G.; MacRaid, C. A.; Anders, R. F. *Biochemistry-Us* **2010**, *49*, 5899.
- (25) Almeida, M. R.; Ferreira, N.; Saraiva, M. J. *FEBS Lett.* **2011**, *585*, 2424.

- (26) Lee, S.; Bae, S. Y.; Kim, S.; Hwang, H.; Kim, H. K.; Yoon, H. C.; Kim, J. H.; Kim, T. D. *Biochem. Biophys. Res. Commun.* **2010**, *400*, 531.
- (27) Norton, R. S.; Chandrashekar, I. R.; Adda, C. G.; MacRaild, C. A.; Anders, R. F. *Arch. Biochem. Biophys.* **2011**, *513*, 153.
- (28) Saraogi, I.; Hebda, J. A.; Becerril, J.; Estroff, L. A.; Miranker, A. D.; Hamilton, A. D. *Angew. Chem. Int. Ed.* **2010**, *49*, 736.
- (29) Meng, F. L.; Raleigh, D. P. *J. Mol. Biol.* **2011**, *406*, 491.
- (30) Knight, J. D.; Williamson, J. A.; Miranker, A. D. *Protein Sci.* **2008**, *17*, 1850.
- (31) Bazar, E.; Sheynis, T.; Dorosz, J.; Jelinek, R. *Chembiochem.* **2011**, *12*, 761.
- (32) Nilsson, M. R. *Methods* **2004**, *34*, 151.
- (33) Fu, L.; Ma, G.; Yan, E. C. Y. *J. Am. Chem. Soc.* **2010**, *132*, 5405.
- (34) Fu, L.; Liu, J.; Yan, E. C. *J. Am. Chem. Soc.* **2011**, *133*, 8094.
- (35) Sovago, M.; Vartiainen, E.; Bonn, M. *J. Phys. Chem. C* **2009**, *113*, 6100.
- (36) Nguyen, K. T.; King, J. T.; Chen, Z. *J. Phys. Chem. B* **2010**, *114*, 8291.
- (37) Chen, X.; Wang, J.; Sniadecki, J. J.; Even, M. A.; Chen, Z. *Langmuir* **2005**, *21*, 2662.
- (38) vandenAkker, C. C.; Engel, M. F. M.; Velikov, K. P.; Bonn, M.; Koenderink, G. H. *J. Am. Chem. Soc.* **2011**, *133*, 18030.
- (39) Kapurniotu, A. *Biopol. Pept. Sci.* **2001**, *60*, 438.
- (40) Knight, J. D.; Hebda, J. A.; Miranker, A. D. *Biochemistry-U.S.* **2006**, *45*, 9496.
- (41) Lopes, D. H. J.; Meister, A.; Gohlke, A.; Hauser, A.; Blume, A.; Winter, R. *Biophys. J.* **2007**, *93*, 3132.
- (42) Mirzabekov, T. A.; Lin, M. C.; Kagan, B. L. *J. Biol. Chem.* **1996**, *271*, 1988.
- (43) Kayed, R.; Sokolov, Y.; Edmonds, B.; McIntire, T. M.; Milton, S. C.; Hall, J. E.; Glabe, C. G. *J. Biol. Chem.* **2004**, *279*, 46363.
- (44) Butterfield, S. M.; Lashuel, H. A. *Angew. Chem. Int. Edit.* **2010**, *49*, 5628.
- (45) Padrick, S. B.; Miranker, A. D. *Biochemistry-U.S.* **2002**, *41*, 4694.
- (46) Engel, M. F. M.; Yigittop, H.; Elgersma, R. C.; Rijkers, D. T. S.; Liskamp, R. M. J.; de Kruijff, B.; Höppener, J. W. M.; Killian, J. A. *J. Mol. Biol.* **2006**, *356*, 783.
- (47) Jayasinghe, S. A.; Langen, R. *Biochim. Biophys. Acta* **2007**, *1768*, 2002.
- (48) Murphy, R. M. *Biochim. Biophys. Acta* **2007**, *1768*, 1923.
- (49) Knight, J. D.; Miranker, A. D. *J. Mol. Biol.* **2004**, *341*, 1175.
- (50) Koo, B. W.; Hebda, J. A.; Miranker, A. D. *Protein Sci.* **2008**, *21*, 147.
- (51) Demel, R. A.; Geurts van Kessel, W. S.; Zwaal, R. F.; Roelofsens, B.; van Deenen, L. L. *Biochim. Biophys. Acta* **1975**, *406*, 97.
- (52) Smits, M.; Sovago, M.; Worpel, G. W. H.; Kim, D.; Muller, M.; Bonn, M. *J. Phys. Chem. C* **2007**, *111*, 8878.
- (53) LeVine, H., 3rd *Meth. Enzymol.* **1999**, *309*, 274.
- (54) Ege, C.; Lee, K. Y. C. *Biophys. J.* **2004**, *87*, 1732.
- (55) Canale, C.; Torrassa, S.; Rispoli, P.; Relini, A.; Rolandi, R.; Bucciattini, M.; Stefani, M.; Gliozzi, A. *Biophys. J.* **2006**, *91*, 4575.
- (56) Gopal, A.; Lee, K. Y. *J. Phys. Chem. B* **2006**, *110*, 22079.
- (57) Wang, J.; Even, M. A.; Chen, X. Y.; Schmaier, A. H.; Waite, J. H.; Chen, Z. *J. Am. Chem. Soc.* **2003**, *125*, 9914.
- (58) Castner, D. G.; Weidner, T.; Apte, J. S.; Gamble, L. J. *Langmuir* **2010**, *26*, 3433.
- (59) Arrondo, J. L. R.; Muga, A.; Castresana, J.; Goni, F. M. *Prog. Biophys. Mol. Biol.* **1993**, *59*, 23.
- (60) Nanga, R. P. R.; Brender, J. R.; Vivekanandan, S.; Ramamoorthy, A. *Biochim. Biophys. Acta* **2011**, *1808*, 2337.
- (61) Huh, N. W.; Porter, N. A.; McIntosh, T. J.; Simon, S. A. *Biophys. J.* **1996**, *71*, 3261.
- (62) Nakayama, T.; Kajiyama, K.; Kumazawa, S. *Biosci. Biotechnol. Biochem.* **2002**, *66*, 2330.

